Polymorphism of the complement receptor 1 gene correlates with the hematologic response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria

Haematologica

Volumn 99, Issue 2, 2014, Pages 262-266

  Rondelli, Tommaso ^a   Risitano, Antonio M ^b   de Latour, Régis Peffault ^c   Sica, Michela ^a   Peruzzi, Benedetta ^a   Ricci, Patrizia ^b   Barcellini, Wilma ^d   Iori, Anna Paola ^e   Boschetti, Carla ^d   Valle, Veronica ^e   Frémeaux Bacchi, Veronique ^f   De Angioletti, Maria ^a,g   Socie, Gerard ^c,h   Luzzatto, Lucio ^a   Notaro, Rosario ^a  

^a ISTITUTO TOSCANO TUMORI   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c SAINT LOUIS HOSPITAL   (France)

^d FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^g Dipartimento di Chimica Organica   (Italy)

^h INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3B RECEPTOR; ECULIZUMAB;

ARTICLE; BLOOD TRANSFUSION; FLOW CYTOMETRY; FOLLOW UP; GENETIC POLYMORPHISM; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; POLYMERASE CHAIN REACTION; PROTEIN POLYMORPHISM; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ANTIBODIES, MONOCLONAL, HUMANIZED; BLOOD TRANSFUSION; COMPLEMENT C3; COMPLEMENT C4; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEMOGLOBINURIA, PAROXYSMAL; HUMANS; MALE; POLYMORPHISM, GENETIC; RECEPTORS, COMPLEMENT 3B;

EID: 84896721048     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.090001     Document Type: Article

References (33)

1. Hillmen P, Young NS, Schubert J, Brodsky RA, Socie G, Muus P, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006;355 (12):1233-43.
2. Luzzatto L, Gianfaldoni G, Notaro R. Management of paroxysmal nocturnal haemoglobinuria: a personal view. Br J Haematol. 2011;153(6):709-20.
3. Kanakura Y, Ohyashiki K, Shichishima T, Okamoto S, Ando K, Ninomiya H, et al. Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS clinical trial. Int J Hematol. 2011;93(1):36-46.
4. Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1995;333(19):1253-8.
5. de Latour RP, Mary JY, Salanoubat C, Terriou L, Etienne G, Mohty M, et al. Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories. Blood. 2008;112(8): 3099-106.
6. Kelly RJ, Hill A, Arnold LM, Brooksbank GL, Richards SJ, Cullen M, et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood. 2011;117(25): 6786-92.
7. Risitano AM, Notaro R, Marando L, Serio B, Ranaldi D, Seneca E, et al. Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. Blood. 2009;113(17):4094-100.
8. Dezern AE, Dorr D, Brodsky RA. Predictors of hemoglobin response to eculizumab therapy in paroxysmal nocturnal hemoglobinuria. Eur J Haematol. 2013;90(1):16-24.
9. Luzzatto L, Risitano AM, Notaro R. Paroxysmal nocturnal hemoglobinuria and eculizumab. Haematologica. 2010;95(4): 523-6.
10. Hill A, Rother RP, Arnold L, Kelly R, Cullen MJ, Richards SJ, et al. Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization. Haematologica. 2010;95(4):567-73.
11. Peruzzi B, Serra M, Pescucci C, Sica M, Lastraioli S, Rondelli T, et al. Easy genotyping of complement C3 'slow' and 'fast' allotypes by tetra-primer amplification refractory mutation system PCR. Mol Cell Probes. 2010;24(6):401-2.
12. Xiang L, Rundles JR, Hamilton DR, Wilson JG. Quantitative alleles of CR1: coding sequence analysis and comparison of haplotypes in two ethnic groups. J Immunol. 1999;163(9):4939-45.
13. Risitano AM, Notaro R, Pascariello C, Sica M, del Vecchio L, Horvath CJ, et al. The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment. Blood. 2012;119(26):6307-16.
14. Sica M, Pascariello C, Rondelli T, Risitano A, R N. Kinetics of complement protein 3 (C3) binding to PNH (GPI-negative) erythrocytes under complement blockade by eculizumab. Haematologica. 2010;95(s3):538.
15. Botto M, Kirschfink M, Macor P, Pickering MC, Wurzner R, Tedesco F. Complement in human diseases: Lessons from complement deficiencies. Mol Immunol. 2009;46(14): 2774-83.
16. Alper CA, Propp RP. Genetic polymorphism of the third component of human complement (C'3). J Clin Invest. 1968;47(9):2181-91.
17. Botto M, Fong KY, So AK, Koch C, Walport MJ. Molecular basis of polymorphisms of human complement component C3. J Exp Med. 1990;172(4):1011-7.
18. Rambausek M, van den Wall Bake AW, Schumacher-Ach R, Spitzenberg R, Rother U, van Es LA, et al. Genetic polymorphism of C3 and Bf in IgA nephropathy. Nephrol Dial Transplant. 1987;2(4):208-11.
19. Appel GB, Cook HT, Hageman G, Jennette JC, Kashgarian M, Kirschfink M, et al. Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. J Am Soc Nephrol. 2005;16(5):1392-403.
20. Maller JB, Fagerness JA, Reynolds RC, Neale BM, Daly MJ, Seddon JM. Variation in complement factor 3 is associated with risk of age-related macular degeneration. Nat Genet. 2007;39(10):1200-1.
21. Wilson JG, Wong WW, Schur PH, Fearon DT. Mode of inheritance of decreased C3b receptors on erythrocytes of patients with systemic lupus erythematosus. N Engl J Med. 1982;307(16):981-6.
22. Wilson JG, Murphy EE, Wong WW, Klickstein LB, Weis JH, Fearon DT. Identification of a restriction fragment length polymorphism by a CR1 cDNA that correlates with the number of CR1 on erythrocytes. J Exp Med. 1986;164(1):50-9.
23. Rowe JA, Raza A, Diallo DA, Baby M, Poudiougo B, Coulibaly D, et al. Erythrocyte CR1 expression level does not correlate with a HindIII restriction fragment length polymorphism in Africans; implications for studies on malaria susceptibility. Genes Immun. 2002;3(8):497-500.
24. Pangburn MK, Schreiber RD, Muller-Eberhard HJ. Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria. Proc Natl Acad Sci USA. 1983;80(17):5430-4.
25. Ross GD, Yount WJ, Walport MJ, Winfield JB, Parker CJ, Fuller CR, et al. Disease-associated loss of erythrocyte complement receptors (CR1, C3b receptors) in patients with systemic lupus erythematosus and other diseases involving autoantibodies and/or complement activation. J Immunol. 1985;135(3):2005-14.
26. Roberts WN, Wilson JG, Wong W, Jenkins DE Jr, Fearon DT, Austen KF, et al. Normal function of CR1 on affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria. J Immunol. 1985;134(1):512-7.
27. Khera R, Das N. Complement receptor 1: disease associations and therapeutic implications. Mol Immunol. 2009;46(5):761-72.
28. Iida K, Nussenzweig V. Complement receptor is an inhibitor of the complement cascade. J Exp Med. 1981;153(5):1138-50.
29. Ross GD, Lambris JD, Cain JA, Newman SL. Generation of three different fragments of bound C3 with purified factor I or serum. I. Requirements for factor H vs CR1 cofactor activity. J Immunol. 1982;129(5):2051-60.
30. Medof ME, Nussenzweig V. Control of the function of substrate-bound C4b-C3b by the complement receptor Cr1. J Exp Med. 1984;159(6):1669-85.
31. Yoshida K, Yukiyama Y, Miyamoto T. Interaction between immune complexes and C3b receptors on erythrocytes. Clin Immunol Immunopathol. 1986;39(2):213-21.
32. Cosio FG, Shen XP, Birmingham DJ, Van Aman M, Hebert LA. Evaluation of the mechanisms responsible for the reduction in erythrocyte complement receptors when immune complexes form in vivo in primates. J Immunol. 1990;145(12):4198-206.
33. Craig ML, Bankovich AJ, Taylor RP. Visualization of the transfer reaction: tracking immune complexes from erythrocyte complement receptor 1 to macrophages. Clin Immunol. 2002;105(1):36-47.